Sarah Sammons, MD, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer treatment
Sarah Sammons, MD
Advertisement
Sarah Sammons, MD, is a medical oncologist and clinical investigator in the Breast Oncology Center, and an associate director of the Metastatic Breast Cancer Program at Dana-Farber Cancer Institute.
Articles by Sarah Sammons, MD
Sarah Sammons, MD, discusses findings from an analysis of the DESTINY-Breast03 trial regarding trastuzumab deruxtecan vs trastuzumab emtansine in the context of HER2-positive breast cancer with brain metastases.
Sarah Sammons, MD, highlights the need for further investigation into trastuzumab deruxtecan in breast cancer treatment.
Sarah Sammons, MD, discusses some of the problems seen with brain metastasis in HER2-positive metastatic breast cancer.
Sarah Sammons, MD, provides an overview of the DESTINY-Breast03 trial.
Advertisement
Latest Updated Articles
Advances in Treating HER2+ Breast Cancer With Brain MetastasesPublished: November 2nd 2024 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
